Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jul 24:366:l4363.
doi: 10.1136/bmj.l4363.

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

Affiliations
Meta-Analysis

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

Faizan Khan et al. BMJ. .

Abstract

Objectives: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.

Design: Systematic review and meta-analysis.

Data sources: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).

Study selection: Randomised controlled trials and prospective cohort studies reporting symptomatic recurrent VTE after discontinuation of anticoagulant treatment in patients with a first unprovoked VTE event who had completed at least three months of treatment.

Data extraction and synthesis: Two investigators independently screened studies, extracted data, and appraised risk of bias. Data clarifications were sought from authors of eligible studies. Recurrent VTE events and person years of follow-up after discontinuation of anticoagulant treatment were used to calculate rates for individual studies, and data were pooled using random effects meta-analysis. Sex and site of initial VTE were investigated as potential sources of between study heterogeneity.

Results: 18 studies involving 7515 patients were included in the analysis. The pooled rate of recurrent VTE per 100 person years after discontinuation of anticoagulant treatment was 10.3 events (95% confidence interval 8.6 to 12.1) in the first year, 6.3 (5.1 to 7.7) in the second year, 3.8 events/year (95% confidence interval 3.2 to 4.5) in years 3-5, and 3.1 events/year (1.7 to 4.9) in years 6-10. The cumulative incidence for recurrent VTE was 16% (95% confidence interval 13% to 19%) at 2 years, 25% (21% to 29%) at 5 years, and 36% (28% to 45%) at 10 years. The pooled rate of recurrent VTE per 100 person years in the first year was 11.9 events (9.6 to 14.4) for men and 8.9 events (6.8 to 11.3) for women, with a cumulative incidence for recurrent VTE of 41% (28% to 56%) and 29% (20% to 38%), respectively, at 10 years. Compared to patients with isolated pulmonary embolism, the rate of recurrent VTE was higher in patients with proximal deep vein thrombosis (rate ratio 1.4, 95% confidence interval 1.1 to 1.7) and in patients with pulmonary embolism plus deep vein thrombosis (1.5, 1.1 to 1.9). In patients with distal deep vein thrombosis, the pooled rate of recurrent VTE per 100 person years was 1.9 events (95% confidence interval 0.5 to 4.3) in the first year after anticoagulation had stopped. The case fatality rate for recurrent VTE was 4% (95% confidence interval 2% to 6%).

Conclusions: In patients with a first episode of unprovoked VTE who completed at least three months of anticoagulant treatment, the risk of recurrent VTE was 10% in the first year after treatment, 16% at two years, 25% at five years, and 36% at 10 years, with 4% of recurrent VTE events resulting in death. These estimates should inform clinical practice guidelines, enhance confidence in counselling patients of their prognosis, and help guide decision making about long term management of unprovoked VTE.

Systematic review registration: PROSPERO CRD42017056309.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: MC has received grants from Leo Pharma, Bristol-Myers Squibb, Bayer, Octapharma, personal fees from Sanofi Aventis, Pfizer, Boehringer Ingelheim, Leo Pharma, Bayer Pfizer, Servier, and been on the advisory board for Leo Pharma and Sanofi Aventis, outside the submitted work; CK has received grants from Bayer, outside the submitted work. JIW has received personal fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb Daiichi-Sankyo, Ionis Pharmaceuticals, Janssen, Merck, Pfizer, and Portola, outside the submitted work; SS has received grants from Boehringer Ingelheim and Octapharma, personal fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo, Octapharma, Sanofi, Alnylam, and Bristol-Myers-Squibb, outside the submitted work; FC has received grants from Pfizer, and personal fees from Bayer, BMS, Aztra Zeneca, leopharma, outside the submitted work; CB has received personal fees from Bayer HealthCare, Daiichi Sankyo, Bristol Myers Squibb, and Servier, outside the submitted work; GA has received personal fees from Bristol-Myers-Squibb, Bayer Healthcare, Boehringer Ingelheim, and Daiichi Sankyo, outside the submitted work; AWAL reports being an employee of Bayer HealthCare; MHP has received personal fees from Pfizer and Daiichi Sankyo, outside the submitted work; BH reports past research from Cornerstone Research Group for methodologic advice related to the conduct of systematic reviews and meta-analysis, outside the submitted work; GP has received personal fees from Alfasigma, Pfizer, BMS, Roche, and Werfen, outside the submitted work. There are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Flow diagram of study identification and selection
Fig 2
Fig 2
Case fatality rate of recurrent venous thromboembolism (VTE) after discontinuation of anticoagulant treatment in patients with a first unprovoked VTE event. P value is for heterogeneity

Comment in

Similar articles

Cited by

References

    1. Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013;347:f5133. 10.1136/bmj.f5133 - DOI - PMC - PubMed
    1. Couturaud F, Sanchez O, Pernod G, et al. PADIS-PE Investigators Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The PADIS-PE randomized clinical trial. JAMA 2015;314:31-40. 10.1001/jama.2015.7046 - DOI - PubMed
    1. Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005;294:706-15. 10.1001/jama.294.6.706 - DOI - PubMed
    1. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010;170:1710-6. 10.1001/archinternmed.2010.367 - DOI - PubMed
    1. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 2011;342:d3036. 10.1136/bmj.d3036 - DOI - PMC - PubMed

Publication types

Grants and funding